Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.82 |
| ▸ | AKT2 | P31751 | 20/20 | 0.82 |
| ▸ | AKT3 | Q9Y243 | 20/20 | 0.82 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.72 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15390637 | 1.00 | AKT1 (0.82) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL3948393 | 1.00 | AKT1 (0.82) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL4982283 | 1.00 | AKT1 (0.82) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL17424856 | 0.90 | AKT1 (1.00) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL191650 | 0.90 | AKT1 (1.00) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL193125 | 0.90 | AKT1 (1.00) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL191301 | 0.89 | AKT1 (0.75) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL192866 | 0.89 | AKT1 (0.75) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL191789 | 0.89 | AKT1 (0.85) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL191788 | 0.89 | AKT1 (0.85) | AKT1AKT2AKT3PIK3CAPRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4282973-A2 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-11-29 | — | — | EP | disclosed |
| EP-3656764-B1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-07-05 | — | — | EP | disclosed |
| EP-2858989-B9 | AMORPHOUS FORM OF AN AKT INHIBITING PYRIMIDINYL-CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | GENENTECH INC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10858324-B2 | Processes for the preparation of pyrimidinylcyclopentane compounds | GENENTECH, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| EP-3719014-A1 | SOLID FORMS OF AN AKT INHIBITING PYRIMIDINYL-CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | Genentech, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3656764-A1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2020-05-27 | — | — | EP | disclosed |
| EP-2858989-B1 | AMORPHOUS FORM OF AN AKT INHIBITING PYRIMIDINYL-CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | GENENTECH INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20200062717-A1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | GENENTECH, INC. (US) | 2020-02-27 | — | — | US | disclosed |
| EP-3068770-B1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2019-10-23 | — | — | EP | disclosed |
| US-10435378-B2 | Processes for the preparation of pyrimidinylcyclopentane compounds | GENENTECH, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180086722-A1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-9862689-B2 | Processes for the preparation of pyrimidinylcyclopentane compounds | GENENTECH, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160297773-A1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| EP-3068770-A1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2016-09-21 | — | — | EP | disclosed |
| US-9315471-B2 | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | GENETECH, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9290458-B2 | Amorphous form of an AKT inhibiting pyrimidinyl-cyclopentane compound, compositions and methods thereof | GENENTECH, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| WO-2015073739-A1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-05-21 | — | — | WO | disclosed |
| US-20150099880-A1 | PROCESS OF MAKING HYDROXYLATED CYCLOPENTAPYRIMIDINE COMPOUNDS AND SALTS THEREOF | GENETECH, INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858324-B2 | Processes for the preparation of pyrimidinylcyclopentane compounds | DHPS, TYMP, DHFR | AKT1 3267/4885AKT2 3039/4885AKT3 3982/4885 |
| US-20180086722-A1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | DHPS, TYMP, DHFR | AKT1 3267/4885AKT2 3039/4885AKT3 3982/4885 |
| US-10435378-B2 | Processes for the preparation of pyrimidinylcyclopentane compounds | DHPS, TYMP, DHFR | AKT1 3267/4885AKT2 3039/4885AKT3 3982/4885 |
| US-20150099880-A1 | PROCESS OF MAKING HYDROXYLATED CYCLOPENTAPYRIMIDINE COMPOUNDS AND SALTS THEREOF | PIK3CA, PIK3CD, PIK3CG | AKT1 10/4885AKT2 6/4885AKT3 20/4885 |
| US-20200062717-A1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | DHPS, TYMP, DHFR | AKT1 3267/4885AKT2 3039/4885AKT3 3982/4885 |
| US-20160297773-A1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | DHPS, TYMP, DHFR | AKT1 3298/4885AKT2 3089/4885AKT3 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.